We recently summarized the outcomes of the BCMA-#CARTcell ide-cel in patients who had received at least 3 prior lines of therapy. At #ASCO21, @ldandersonjr presents the KarMMa trial with longer follow-up and OS results in important subgroups #mmsm 👇https://t.co/94CZeaY0kK
— Multiple Myeloma Hub (@MM_Hub) June 8, 2021